Efficasy and safety of bevacizumab in combination with chemotherapy for treating the first recurrence of ovarian carcinoma : Phase 2 study

Trial Profile

Efficasy and safety of bevacizumab in combination with chemotherapy for treating the first recurrence of ovarian carcinoma : Phase 2 study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Docetaxel; Doxorubicin; Gemcitabine; Irinotecan; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jul 2017 Planned End Date changed from 1 Oct 2019 to 31 Mar 2018.
    • 06 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top